Cognitive computing powerhouse IBM Watson Health is adding novel offerings and entering new agreements in an array of healthcare arenas.
This week, IBM Watson Health announced a slew of solutions and partnerships aimed at improving healthcare decision making and delivery. The announcement, which was released during a major gathering for the health IT community--the annual Healthcare Information and Management Systems Society (HIMSS) conference--covers offerings focused on value-based care, medical imaging, and population health.
"Healthcare organizations are operating in a complex and fluctuating business environment, one in which the insights they need to succeed can be hidden amidst an avalanche of disparate and siloed data," Deborah DiSanzo, general manager of IBM Watson Health, said in a press release. She added, "Watson Health's extensive industry expertise informs how we deploy data, cloud, and cognitive computing to help clients make more informed decisions today and understand precisely what their organization should address to achieve their quality care goals and outcomes in a value-based care system."
Among the new products is the IBM Watson Health Value-Based Care solutions. Applications set to be released later in 2017 include solutions that help track and forecast value-based care performance indicators, monitor patient engagement, customize analytics, and tools that can help pinpoint areas of high cost.
IBM also unveiled IBM Watson Imaging Clinical Review, choosing to focus first on aortic stenosis. The offering is designed to alert clinicians to patients who may have aortic stenosis but haven't been identified as a candidate for cardiovascular follow up care, according to a press release. The platform is expected to eventually be expanded to nine more cardiovascular diseases, including cardiomyopathy, deep vein thrombosis, heart attacks, among others.
"Out of the gate, this type of cognitive tool may provide big benefits to hospitals and doctors, providing insights we don't currently have and doing so in a way that fits how we work," Ricard Cury, MD, director of cardiac imaging at Baptist Health of South Florida and chairman and CEO of Radiology Associates of South Florida, said in the release.
Cury's institutions are among the new members of the Watson Health medical imaging collaborative, focused on optimizing the applications of medical imaging. IBM announced in the imaging release that there are now 24 organizations in the collaborative.
Another agreement announced the same day will bring the more than 2000 healthcare providers of the Central New York Care Collaborative (CNYCC) onto a population health platform run on the Watson Health Cloud. The effort aims to cut Medicaid costs and preventable emergency room visits, as well as cut hospital readmissions by 25%, according to a news release.
"Central New York is leading the way for a national movement toward an effective, scalabe patient-centric approach to population health management and value-based care," Anil Jain, MD, FACP, vice president and chief health informatics officer, Value-Based Care at IBM Watson Health, said in the release.
IBM Watson Health also signed on to an agreement with a healthcare organization, Atrius Health. The collaboration will center around more information that can be used to facilitate shared decision making and Improve delivery of patient care in the eastern Massachusetts region covered by the healthcare organization.
"Atrius Health is committed to increasing the joy in the practice of medicine for our clinicians and staff," Steve Strongwater, MD, president and CEO of Atrius Health, said in a news release. "Working with IBM Watson Health offers a unique opportunity to help our Atrius Health clinicians make greater use of the mountains of digitalized information generated daily through our care of patients."
Of course, there's more to these new collaborations than the exciting potential of the technology. Forbes reported recently that a partnership between IBM Watson and MD Anderson has been paused, highlighting the important role that project management and finances--in addition to the technology--play in the success of such a joint effort.
IBM Watson Health already has an impressive list of collaborations under its belt, including with Quest Diagnostics, Medtronic, Johnson & Johnson, and Memorial Sloan Kettering. More partnerships seem likely, as IBM also debuted its Watson Health Consulting Services unit and new features for its Watson Platform for Health Cloud this week. These offerings echo IBM Watson Health's other priorities, with a continued focus on quicker, better insights, improved patient care, and value-based care.
"The launch of the new Watson Health Consulting Services unit is about helping our clients transform healthcare, in quality, improved access, patient satisfaction and lower cost in the cognitive healthcare era," Matt Porta, vice president and partner for IBM Watson Health Consulting Group, said in the release.
[Image courtesy of FRANKY242/FREEDIGITALPHOTOS.NET]
IBM shook up the digital health space Friday with the news that it is selling its healthcare data and analytics assets, currently part of the Watson Health business, to an investment firm. The sale price is reportedly more than $1 billion, although the companies are not officially disclosing the financial terms.
There are a lot of interesting factors to consider as we unpack this news, although some thought leaders say the divestiture did not come as a surprise.
“The Watson Health sale has been anticipated for quite some time. IBM was clearly not gaining much traction in the healthcare market while others such as Google and Microsoft have pulled ahead. Even Oracle has made a big splash in healthcare with its exact announcement to acquire Cerner," said Paddy Padmanabhan, founder and CEO of Damo Consulting, a growth strategy and digital transformation advisory firm that works with healthcare and technology companies.
IBM was one of the first big tech companies to dive into healthcare with its well-known Watson Health supercomputer known for defeating the greatest champions on “Jeopardy!" The platform created a lot of buzz back in 2011, and many people had high hopes for the platform's potential applications in healthcare. In exact years, however, that buzz has significantly died down.
"In the current competitive landscape, IBM would not be considered a significant player in healthcare. Selling off the data assets essentially means an end to the Watson Health experiment; however, it may allow IBM as an organization to refocus and develop a new approach to healthcare,” Padmanabhan said.
Assuming there are no regulatory snags, the deal is expected to close in the second quarter of this year.
“Today’s agreement with Francisco Partners is a clear next step as IBM becomes even more focused on our platform-based hybrid cloud and AI strategy,” said Tom Rosamilia, senior vice president of IBM Software. “IBM remains committed to Watson, our broader AI business, and to the clients and partners we support in healthcare IT. Through this transaction, Francisco Partners acquires data and analytics assets that will benefit from the enhanced investment and expertise of a healthcare industry focused portfolio.”
The agreement calls for the current management team to continue in similar roles in the new standalone company, serving existing clients in life sciences, provider, imaging, payer and employer, and government health and human services sectors.
“We have followed IBM’s journey in healthcare data and analytics for a number of years and have a deep appreciation for its portfolio of innovative healthcare products,” said Ezra Perlman, co-president at Francisco Partners. “IBM built a market-leading team and provides its customers with mission critical products and outstanding service.”
In 2016 IBM doubled the size of its Watson Health business through the $2.6 billion acquisition of Truven Health Analytics. Truven offers healthcare data services targeted at employers, hospitals, and drug companies, and makes software that can parse through millions of patient records. Truven's main offices are in Ann Arbor, MI, Chicago, and Denver. At the time of the acquisition, Truven had around 2,500 employees.
The Truven deal followed other major healthcare acquisitions in the company, including Cleveland-based Explorys, Dallas-based Phytel, and Chicago-based Merge Healthcare. The company paid about $1 billion for Merge.
IBM said the assets acquired by Francisco Partners include extensive and diverse data sets and products, including Health Insights, MarketScan, Clinical Development, Social Program Management, Micromedex, and imaging software offerings.
Padmanabhan said it will be interesting to see how the new owners are able to leverage those data assets.
“IBM’s decision to sell its data assets is an indication that it’s not just enough to have the data. Applying advanced analytics on the data to generate insights that can make a difference in real-world applications is where the true value lies. IBM had several missteps early on, especially in cancer care applications, that created significant setbacks for the business that they could not recover from.
In 2018, the Watson Health business went through a round of layoffs. The company declined to tell MD+DI at the time how many of employees were let go other than to say it was a "small percentage" of the global business, but online commenters on TheLayoff.com and Watching IBM, along with multiple news reports citing unnamed sources from within the organization painted a different picture of the situation. One Dallas-based commenter on TheLayoff.com said that "we all knew it was coming but nobody expected it to be this fast and rampant," while another commenter estimated that 80% of that same Dallas-based office was let go.
While we have seen a trend in exact years with big tech firms showing an interest in healthcare, some of those companies are finding those efforts to be easier said than done.
“IBM’s decision to sell the Watson Health assets is another instance of a big tech firm acknowledging the challenges of the healthcare space. Last year, Google and Apple had significant setbacks, and Amazon has acknowledged challenges in scaling its Amazon Care business," Padmanabhan said. "In IBM’s case, they have missed out on the cloud opportunity and have lagged behind peers in emerging technology areas such as voice. While IBM’s challenges with Watson Health may have been unique to the organization, the fact is that big tech firms have multiple irons in the fire at any time, and for some healthcare may just be too hard.”
Padmanabhan does not think, however, that IBM's decision to sell the Watson Health assets is an indictment of the promise of AI in healthcare.
"Our research indicates AI was one of the top technology investments for health systems in 2021," he said. "Sure, there are challenges such as data quality and bias in the application of AI in the healthcare context, but by and large there has been progress with AI in healthcare. The emergence of other players, notably Google with its Mayo Partnership, or Microsoft with its partnership with healthcare industry consortium Truveta are strong indicators of progress."
Padmanabhan is co-author with Edward W. Marx, of Healthcare Digital Transformation: How Consumerism, Technology and Pandemic are Accelerating the Future (2020), and the host of The Big Unlock, a podcast focusing on healthcare digital transformation.
IE 11 is not supported. For an optimal experience visit our site on another browser.
New Jersey, United States, Oct. 13, 2022 /DigitalJournal/ The Population Health Management Market research report provides all the information related to the industry. It gives the markets outlook by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments, and manufacturing technology. This Population Health Management market research report tracks all the exact developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.
Population health management refers to the process of improving the clinical health outcomes of a defined group of people through better coordination of care and patient engagement supported by appropriate financial and care models. The medical industry is rapidly transforming from a paper-based system to a digitized system, accelerating the demand for healthcare IT services. In addition, the growing demand for solutions that support value-based care delivery by healthcare stakeholders has resulted in a shift from fee-for-service (FFS) models to fee-based payment models. value (VBP). Increasing demand for effective disease management strategies is also expected to drive market growth.
Get the PDF sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:
This Population Health Management research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status, and upcoming products.
Some of the Top companies Influencing this Market include:IBM, Optumhealth, Cerner, Healthagen, Verscend Technologies, I2I Population Health, Epic, Orion Health, Forward Health, Change Healthcare, GSI Health, EClinicalWorks,
Firstly, this Population Health Management research report introduces the market by providing an overview that includes definitions, applications, product launches, developments, challenges, and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristics is provided in the Population Health Management report.
The region-wise coverage of the market is mentioned in the report, mainly focusing on the regions:
Segmentation Analysis of the market
The market is segmented based on the type, product, end users, raw materials, etc. the segmentation helps to deliver a precise explanation of the market
Market Segmentation: By Type
Market Segmentation: By Application
Payers, Providers, Employers,
For Any Query or Customization: https://a2zmarketresearch.com/ask-for-customization
An assessment of the market attractiveness about the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants in the global Population Health Management market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.
This report aims to provide:
Table of Contents
Global Population Health Management Market Research Report 2022 – 2029
Chapter 1 Population Health Management Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10 Marketing Strategy Analysis, Distributors/Traders
Chapter 11 Market Effect Factors Analysis
Chapter 12 Global Population Health Management Market Forecast
Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout
1887 WHITNEY MESA DR HENDERSON, NV 89014
+1 775 237 4157
Technology stocks have been battered for most of 2022. There are many names that I consider of the highest quality that have been absolutely destroyed this year, but that's not the case for all tech stocks. In fact, IBM (NYSE:IBM) has bucked the trend and has actually outperformed the broader market by a wide margin in 2022.
I've made it no secret that I don't see any reason to own IBM, including in my last update back in March. I said then the ~5% yield wasn't good enough to warrant owning the shares, unless you are focused on income and nothing else. Today, even though IBM has returned -5% since that article against -18% for the S&P 500, I still don't think this is one you want to own near a market bottom. The reason is simple; IBM is a defensive stock in tech - if there is such a thing - which is why it has outperformed this year during a horrendous bear market. When we turn higher, defensive names are the last thing you want to own, so I'm sticking to my sell call here.
Looking at the daily chart, I don't see a lot of cause for long-term optimism, although the stock is oversold on a short-term basis. We can see there have been several rally attempts, but all have ultimately resulted in another turn lower. This current rally attempt is the result of a long string of declines that produced a PPO memorizing near -2, which is where the stock has bounced in the past. This one is no different, but do not mistake a bounce for a rally.
The 14-day RSI, which is a shorter-term indicator than the PPO, hasn't cleared the centerline in the past two rally attempts. That's the sign of a stock with a lack of bullish momentum, and it's why I said not to mistake a bounce for a rally; this is one of the ways you can tell the difference.
On a relative strength basis, as I said, IBM has been great this year. It's convincingly outperformed its peer group, which in turn, has outperformed the S&P 500. That's the kind of thing you want to see from your stocks, but as I said, given IBM is defensive in the tech group, this outperformance makes sense during a bear market. Rest assured this relative strength will flip on its head when we do turn higher, because Wall Street wants exposure to growth during bull markets, and IBM simply doesn't have it.
I've long maintained that IBM is a company that struggles to hit its own guidance, and therefore, estimates that Wall Street produces. This is, of course, highly undesirable because it means that when investors try to value the stock, they are doing so with shrinking estimates. Plus, there aren't many investors that want a stock with shrinking estimates, given those stocks that perform the best are the ones consistently raising guidance and beating estimates. IBM hasn't been one of those stocks in decades, literally, and today is no different.
Let's take a look at revenue, beginning with a historical view of its three major segments.
One of the things you must understand about IBM's revenue is that it is choppy. All of its segments produce oscillating revenue - rather than steadily growing revenue - and that generates the same on a consolidated enterprise basis. This is not a desirable trait, and it means that even though there's clear leadership from software, even that segment has struggled in the past to produce growth.
The most exact quarter saw software produces 8% growth in annual recurring revenue, which is fine, with the best growth from transaction processing. Red Hat continues to be a growth driver for IBM, and in my opinion, is one of the best things this company has ever done with its capital. The second best thing was spinning off Kyndryl (KD), which is now a significant customer of IBM. Kyndryl is obviously a captive audience when it comes to revenue for IBM, so as long as Kyndryl is around, IBM has some built-in software revenue growth.
But as we can see, that simply hasn't been enough, and I don't think it ever will be based on IBM's history of missing its own guidance. Below are revenue estimates for the next few years, and the revision history of those estimates.
We're looking at current estimates of 3% or 4% growth annually, but with nearly-constant revisions downward to those. The best the company can show is a lack of negative revisions on this year's numbers in the past month; it's a sad state of affairs. However, anyone that has followed IBM for any period of time knows one thing this company is always good for is missing estimates. This is not new.
Moving to earnings, below we have the same chart as above, but with earnings before taxes instead of revenue.
Software's dominance is very clear here, given margins are much better than the other segments. That means that if you insist on owning this stock for whatever reason, you want to keep a desparate eye on software's performance. The others simply don't matter nearly as much when it comes to earnings and cash flow. The fact that IBM has some growth drivers in software is a good sign, but is it enough to overcome weakness elsewhere? You can be the judge of that.
We've touched on two of the drivers of EPS growth - revenue and margins - but IBM has spent tens of billions of dollars buying back its own shares in the past couple of decades. The company's "strategy" used to just be to milk as much cash from its business as possible and then spend almost all of it on repurchases, hoping financial engineering would work its magic into EPS growth. While I'm a fan of buybacks when they're done correctly, IBM's blunt force approach never worked because it forgot to stay competitive in the marketplace. Newer leadership is focusing more on the actual business rather than just buying as many shares as possible, but the end result doesn't appear to be that different.
EPS revisions just continue to go lower, and it's still happening today, as it has for many years. This makes it challenging to value IBM on a P/E basis because you simply don't know how low the "E" part of the equation will go. That's also why Wall Street prefers stocks with growing "E" values because it means the share price must rise in order to maintain the same valuation; IBM has the opposite issue.
What's interesting is that despite IBM's complete inability to even meet estimates - let alone beat them - the stock is actually quite near its highs in terms of valuation. Below we have five years of history of forward P/E ratios to illustrate this point.
The stock trades today at 13X forward earnings, against a five-year average of 11X. It's certainly in the upper echelons of historical valuations, which is perhaps understandable given 2022 has been awful for the markets, and therefore good for defensive names. However, this overvaluation (as I see it) should unwind pretty quickly once the bull market returns. I'm of the view that the bull market has either already begun again or is quite close to doing so, and given that, names like IBM will almost certainly be discarded to the back burner again.
One quick note on the dividend is that IBM's yield is exemplary at 5.2%. It's a proper income stock, and as we can see, the yield is very high by historical standards.
If you're a pure income investor, maybe that's good enough for you to own it. I'm not, and I see no reason to own this stock other than the yield, if that's your thing.
We have a stock that is overvalued on a historical basis, has very little growth to speak of, years and years of declining revenue and earnings estimates, and no catalysts that I can see that would change any of those characteristics. The chart looks pretty weak to me, and this appears to be a bounce, and not a rally. I'm sticking to my sell recommendation for IBM as I think it's relative outperformance in 2022 is coming to an end.
To determine the hospitals included on the Fortune/IBM Watson Health 100 Top Hospitals list, IBM Watson Health researchers evaluated 3,134 short-term, acute care, nonfederal U.S. hospitals. All research was based on the following public data sets: Medicare cost reports, Medicare Provider Analysis and Review (MEDPAR) data, and core measures and patient satisfaction data from the Centers for Medicare & Medicaid Services (CMS) Hospital Compare website. Hospitals do not apply for awards, and winners do not pay to market this honor.
Fortune/IBM Watson Health 100 Top Hospitals 2020: Health Systems
Fortune/IBM Watson Health 100 Top Hospitals 2020: Teaching Hospitals
Fortune/IBM Watson Health 100 Top Hospitals 2020: Community Hospitals
To determine the hospitals included on the IBM Watson Health 15 Top Health Systems list, IBM Watson Health researchers evaluated 332 health systems and 2,492 hospitals that are members of health systems. All research was based on the following public data sets: Medicare cost reports, Medicare Provider Analysis and Review (MEDPAR) data, and core measures and patient satisfaction data from the Centers for Medicare & Medicaid Services (CMS) Hospital Compare website.
Final rank is determined based on performance for all individual measures. Hospitals are ranked within their class definition group. Rankings (scores) within measure domain are relative to the winner class universe only. Lower numbers indicate the best scores.
Hospital measure domains
11 measures distributed across five domains.
There are six clinical measures used in the scorecard. Measures include (1) risk-adjusted IP mortality, (2) risk-adjusted complications, (3) health care associated infections,* (4) influenza immunization, (5) 30-day mortality, and (6) 30-day readmissions. *Health care associated infections are excluded for the Small Community Hospitals class. Rankings (scores) within measure domain are relative to the winner class universe only. Lower numbers indicate the best scores.
There are three operational efficiency measures used in the scorecard: (1) emergency department throughout, (2) severity adjusted length of stay, and (3) adjusted inpatient expense per discharge. Rankings (scores) within measure domain are relative to the winner class universe only. Lower numbers indicate the best scores.
The patient experience measure reflects the overall patient rating from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey tool. Rankings (scores) within measure domain are relative to the winner class universe only. Lower numbers indicate the best scores.
The financial health measure used in the scorecard is adjusted operating profit margin. Rankings (scores) within measure domain are relative to the winner class universe only. Lower numbers indicate the best scores.
Each hospital is defined within a class based on their bed size and teaching status.
Major Teaching: 207 Hospitals
Teaching: 560 Hospitals
Large Community: 270 Hospitals
Medium Community: 812 Hospitals
Small Community: 831 Hospitals
IBM, Watson Health and 100 Top Hospitals are registered trademarks of International Business Machines Corporation in the United States and other countries. FORTUNE is a trademark of Fortune Media IP Limited; registered in the U.S. and other countries.
This page shows the latest IBM Watson Health news and features for those working in and with pharma, biotech and healthcare.
old project with IBM Watson Health applying AI to real-world data to Improve insight on the expected outcomes of breast cancer treatment.
It’s a road whose signposts point strongly towards data, with the tech firms attending a two-day EMA workshop in November 2016 - among them IBM Watson Health and Google - having ... R&D, this time within psychiatric and neurological treatments, was in
IBM Watson Health/ Illumina. Partnership to integrate Watson for Genomics into Illumina's BaseSpace Sequence Hub and tumour sequencing process to expand access to genomic data. ... Novo Nordisk/Glooko. Non-exclusive collaboration to deliver
licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food. ... acquisition of 85.1% stake. 60. Broad Institute/ IBM Watson Health. reserch
If you ask 50 different people for a definition of digital health, you'd probably get 50 different views. ... The intersection of digital health, data and - hopefully - actionable insights was the focus of a particularly interesting deal Novo recently
NHS Digital has awarded IBM a £52.4 million ($60.2 million) contract for supporting and developing the NHS App, which the UK government plans to make the standard way for health services to communicate with patients.…
In a contract award notice published late last month, the now defunct Department of Health agency said Big Blue had won the deal for consulting, software development, and support for the NHS App, first launched in early 2019.
"The NHS's Long-Term Plan objectives state that the NHS App will create a standard online way for people to access the NHS and that the app will work seamlessly with other services at national and local levels and, where appropriate, be integrated into patient pathways," the notice said.
The notice added that the NHS App gives patients access to core NHS transaction services and visibility of their records.
Currently available for obtain in both the Apple and Google Play stores, the NHS App provides a "simple and secure way for people to access a range of NHS services on their mobile device or computer," the notice said.
The deal with IBM is set to last four years and end in June 2026.
The NHS App preceded the COVID-19 track and trace app developed by NHS Test and Trace. The first iteration of the Test and Trace app never really launched and was abandoned in preference for a model developed by Google and Apple.
The NHS App does play a role in the pandemic recovery by supporting so-called vaccine passports.
In May last year, the NHS App started to register vaccination status, despite warnings that the technology could lead to identifiable medical information being exposed.
A study by campaign group Big Brother Watch concluded that COVID certificates using the NHS App would be "intrinsically linked to individuals' identities... as NHS records contain a wealth of identifiable, sensitive information including NHS numbers."
That report [PDF] stated: "Using the NHS App for proof of a vaccine comes with a significant further privacy risk due to the wealth of other personal information available within it, from prescriptions to addresses, and these issues are yet to be addressed." ®
New Jersey, NJ -- (SBWIRE) -- 10/09/2022 -- Latest Study on Industrial Growth of Worldwide Health Insurance Exchange Market 2022-2028. A detailed study accumulated to offer Latest insights about acute features of the Worldwide Health Insurance Exchange market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis.
The Major Players Covered in this Report: Accenture, CGI, Deloitte, IBM, Infosys, MAXIMUS, Oracle, Xerox, Connecture, Cognosante, HCentive, Hexaware Technologies, HP, Inovalon, Inc., KPMG, Microsoft, Noridian Healthcare Solutions, Tata Consultancy Services (TCS), Wipro, Health Insurance Exchange markets by :, In North America, In Latin America, Europe, The Asia-pacific & Middle East and Africa (MEA)
Worldwide Health Insurance Exchange Market Study guarantees you to remain / stay advised higher than your competition. With Structured tables and figures examining the Worldwide Health Insurance Exchange, the research document provides you a leading product, submarkets, revenue size and forecast to 2027. Comparatively is also classifies emerging as well as leaders in the industry.
Click To get sample PDF of Worldwide Health Insurance Exchange Market (Including Full TOC, Table & Figures) @ https://www.htfmarketreport.com/sample-report/3707010-worldwide-health-insurance-exchange-market
This study also covers company profiling, specifications and product picture, sales, market share and contact information of various regional, international and local vendors of Worldwide Health Insurance Exchange Market. The market proposition is frequently developing ahead with the rise in scientific innovation and M&A activities in the industry. Additionally, many local and regional vendors are offering specific application products for varied end-users. The new merchant applicants in the market are finding it hard to compete with the international vendors based on reliability, quality and modernism in technology.
Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/3707010-worldwide-health-insurance-exchange-market
The titled segments and sub-section of the market are illuminated below:
In-depth analysis of Worldwide Health Insurance Exchange market segments by Types: Software & Hardware
Detailed analysis of Worldwide Health Insurance Exchange market segments by Applications: Government Agencies, Third Party Administrators (TPAs) & Health Plans or Payers
Major Key Players of the Market: Accenture, CGI, Deloitte, IBM, Infosys, MAXIMUS, Oracle, Xerox, Connecture, Cognosante, HCentive, Hexaware Technologies, HP, Inovalon, Inc., KPMG, Microsoft, Noridian Healthcare Solutions, Tata Consultancy Services (TCS), Wipro, Health Insurance Exchange markets by : In North America, In Latin America, Europe, The Asia-pacific & Middle East and Africa (MEA)
Regional Analysis for Worldwide Health Insurance Exchange Market:
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
- North America (U.S., Canada, and Mexico)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (Saudi Arabia, UAE, South Africa)
Furthermore, the years considered for the study are as follows:
Historical year – 2016-2021
Base year – 2021
Forecast period** – 2022 to 2027 [** unless otherwise stated]
**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.
Buy Latest Edition of Market Study Now @ https://www.htfmarketreport.com/buy-now?format=1&report=3707010
Key takeaways from the Worldwide Health Insurance Exchange market report:
– Detailed considerate of Worldwide Health Insurance Exchange market-particular drivers, Trends, constraints, Restraints, Opportunities and major micro markets.
– Comprehensive valuation of all prospects and threat in the – In depth study of industry strategies for growth of the Worldwide Health Insurance Exchange market-leading players.
– Worldwide Health Insurance Exchange market latest innovations and major procedures.
– Favorable dip inside Vigorous high-tech and market latest trends remarkable the Market.
– Conclusive study about the growth conspiracy of Worldwide Health Insurance Exchange market for forthcoming years.
What to Expect from this Report On Worldwide Health Insurance Exchange Market:
1. A comprehensive summary of several area distributions and the summary types of popular products in the Worldwide Health Insurance Exchange Market.
2. You can fix up the growing databases for your industry when you have info on the cost of the production, cost of the products, and cost of the production for the next future years.
3. Thorough Evaluation the break-in for new companies who want to enter the Worldwide Health Insurance Exchange Market.
4. Exactly how do the most important companies and mid-level companies make income within the Market?
5. Complete research on the overall development within the Worldwide Health Insurance Exchange Market that helps you elect the product launch and overhaul growths.
Enquire for customization in Report @ https://www.htfmarketreport.com/enquiry-before-buy/3707010-worldwide-health-insurance-exchange-market
Detailed TOC of Worldwide Health Insurance Exchange Market Research Report-
– Worldwide Health Insurance Exchange Introduction and Market Overview
– Worldwide Health Insurance Exchange Market, by Application [Government Agencies, Third Party Administrators (TPAs) & Health Plans or Payers]
– Worldwide Health Insurance Exchange Industry Chain Analysis
– Worldwide Health Insurance Exchange Market, by Type [Services, Software & Hardware]
– Industry Manufacture, Consumption, Export, Import by Regions (2016-2021)
– Industry Value ($) by Region (2016-2021)
– Worldwide Health Insurance Exchange Market Status and SWOT Analysis by Regions
– Major Region of Worldwide Health Insurance Exchange Market
i) Worldwide Health Insurance Exchange Sales
ii) Worldwide Health Insurance Exchange Revenue & market share
– Major Companies List
Thanks for memorizing this article; you can also get individual chapter wise section or region wise report version like North America, MINT, BRICS, G7, Western / Eastern Europe or Southeast Asia. Also, we can serve you with customize research services as HTF MI holds a database repository that includes public organizations and Millions of Privately held companies with expertise across various Industry domains.
For more information on this press release visit: http://www.sbwire.com/press-releases/health-insurance-exchange-market-may-see-a-big-move-ibm-infosys-hp-1362171.htm
Nidhi BhawsarPR & Marketing Manager
HTF Market Intelligence Consulting Pvt. Ltd.
Email: Click to Email Nidhi Bhawsar